2 terminated. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Terminated 2 |
| Phase 2 | 2 | Terminated 2 |
Follow Kronos Bio: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) Lanraplenib, Gilteritinib - Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia | Phase 1 / Phase 2 | Terminated | Kronos Bio | 24 | 2022-08-05 | 2024-08-07 |
| A Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors Including Platinum Resistant High Grade Serous Ovarian Cancer (HGSOC) KB-0742 - Relapsed Solid Tumors, Refractory Solid Tumors | Phase 1 / Phase 2 | Terminated | Kronos Bio | 135 | 2021-02-08 | 2025-02-17 |
Leukemia, Myeloid, Acute (1) · Lymphoma, Non-Hodgkin (1)
gilteritinib (1)
Spain (2) · United States (2) · United Kingdom (1)
2023 (1)